oral glp-1 drugs in development Receptor Agonist Market Size & Analysis, 2026-2033 Emerging Trends in the Development

Switches within the categories of other GLP-1 receptor agonists and other SGLT2 inhibitors were considered as switches but were not further categorised due to the low number of such switches

Your metabolic health is our passion

Novo Nordisks Wegovy (semaglutide), the first and only once-weekly GLP-1 receptor agonist approved for weight management in people with obesity, has been found to help patients lose up to 15 percent of their body weight in over 68 weeks

E., van Raalte, D

A recent observational study found that rates of DR progression with GLP-1 RA treatment were comparable with those of patients receiving no hypoglycemic agents

Scientific and investor interest in ibogaine and related psychedelic-derived therapeutics has grown considerably in recent years, as researchers examine their potential applications in addiction treatment, mental health conditions, and neurological disorders